Beryl Drugs chairman and AGM
BSE: 524606Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 28 Oct 2026. Previous close ₹23.75.
28 Oct: open ₹27.80, high ₹27.80, low ₹23.06
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13 Cr4,587th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 20.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.33
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 6.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.24
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 1,288
Beryl Drugs' chairperson is SUDHIR SETHI, as filed for the quarter to Dec 2024. Its latest annual general meeting was on 29 Sep 2026.
Beryl Drugs board of directors
At the end of the quarter to Dec 2024, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonSUDHIR SETHI
4 directors2 independent1 executive1 non-executive
- SANJAY SETHIExecutive · joined Dec 2000 · 2 listed boards · 1 committee seat
- SUDHIR SETHI · ChairpersonNon-executive · joined Dec 2000 · 2 listed boards · 1 committee seat
- SHREYA SARAFIndependent · joined May 2019 · 72 months as independent · 1 listed board · 1 as independent · 1 committee seat
- ABHINAV NAIKIndependent · joined May 2019 · 72 months as independent · 2 listed boards · 1 as independent · 1 committee seat, 1 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 13 Nov 20244 of 4 present2 independent · 70 days in between
- 3 Sep 20244 of 4 present2 independent · 55 days in between
- 9 Jul 20244 of 4 present2 independent
Audit Committee
Chair ABHINAV NAIK
SUDHIR SETHI, SHREYA SARAF
- 13 Nov 20243 of 3 present2 independent · 95 days in between
- 9 Aug 20243 of 3 present2 independent
Nomination and remuneration committee
Chair ABHINAV NAIK
SUDHIR SETHI, SHREYA SARAF
No meeting listed in the filing.
Stakeholders Relationship Committee
Chair ABHINAV NAIK
SUDHIR SETHI, SHREYA SARAF
- 1 Nov 20243 of 3 present2 independent · 114 days in between
- 9 Jul 20243 of 3 present2 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Subhash Chand Jain Anurag & AssociatesPeer-review certificate valid to Mar 2027
1 earlier auditor
- SUBHASH CHAND JAIN ANURAG AND ASSOCIATESNamed in the filing for the quarter to Mar 2025
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Beryl Drugs AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.
Annual general meeting, 29 Sep 2026
7,351 shareholders on the register on 22 Sep 2026; present: 4 promoters and 43 others; votes counted by DIPIKA KATARIA / DIPIKA KATARIA.The company's voting result
To receive, consider and adopt the audited standalone financial statements of the Company for the financial year ended as on 31st March 2026, along with the reports of Board of Directors and the Auditors thereon.MoreLess
Ordinary100.00% for0.00% againstAgainst: promoters 0.00% · other public 0.00%
Turnout: all 63.85% · promoters 100.00% · other public 49.82%
- To appoint a Director in place of Mr. Sudhir Sethi (DIN: 00090172), who retires by rotation and, being eligible, offers himself for re-appointmentOrdinary99.68% for0.32% against
Against: promoters 0.00% · other public 0.57%
Turnout: all 63.85% · promoters 100.00% · other public 49.82%
- Approval for increase in the limit of material related party transactions with m/s. Aminova infusions pvt. LtdOrdinary99.68% for0.32% against
Against: promoters 0.00% · other public 0.57%
Turnout: all 63.85% · promoters 100.00% · other public 49.82%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Compliance
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
The company's own answers in its filing.